SERVE-HF: More Questions Than Answers

Area of Science:

• Cardiology
• Pulmonology
• Sleep Medicine
• Medical Device Technology

Background:

• The SERVE-HF trial investigated adaptive servoventilation (ASV) for central sleep apnea (CSA) in patients with heart failure and reduced ejection fraction (HFrEF).
• Published results indicated ASV was ineffective and associated with increased cardiovascular mortality in treated patients.
• The trial authors suggested CSA might be a compensatory mechanism in HFrEF, explaining the adverse outcomes.

Purpose of the Study:

• To critically evaluate the SERVE-HF trial findings regarding ASV treatment for CSA in HFrEF patients.
• To propose alternative explanations for the trial's safety concerns and ineffectiveness findings.
• To highlight potential methodological limitations and confounding factors not adequately addressed in the original study.

Main Methods:

• Commentary and critical analysis of the SERVE-HF trial data and published results.
• Examination of potential methodological issues, including the ASV device generation and constrained therapeutic settings.
• Consideration of patient selection, data collection, adherence, and group crossovers as potential confounding factors.

Main Results:

• The commentary questions the trial's conclusion that CSA is a protective mechanism in HFrEF.
• Identified potential limitations in the ASV device used, which may not reflect current clinical practice.
• Suggested that methodological shortcomings and unaddressed confounding factors could explain the observed adverse outcomes.

Conclusions:

• The results of the SERVE-HF trial may be influenced by factors beyond the primary hypothesis.
• Further post hoc analysis of the SERVE-HF data is warranted to explore alternative explanations.
• This analysis provides critical insights for clinicians managing HFrEF patients with CSA.